Validation of the Turkish BRIEF-HINE Neurological Test for At-Risk Infants Aged 3 to 12 Months

What this Trial Is About

Researchers are studying infants at risk of neurological and developmental problems, including those born prematurely or with conditions like hypoxic-ischemic encephalopathy, intraventricular hemorrhage, and other serious health issues. The goal is to validate a shorter Turkish version of the BRIEF-Hammersmith Infant Neurological Examination HINE to enable earlier and easier detection of developmental concerns in at-risk infants aged 3 to 12 months. The study will include about 110 at-risk infants referred for follow-up at a Pediatric Rehabilitation Unit. The infants will be assessed using both the full Hammersmith Infant Neurological Examination and the BRIEF-HINE at 3, 6, and 12 months of age. The study focuses on evaluating the validity and reliability of the shorter BRIEF-HINE tool compared to the standard HINE method. Participants will undergo neurological examinations at these three time points along with completing a sociodemographic form at the initial assessment. Researchers will measure the infants neurological status to determine how well the BRIEF-HINE performs in detecting developmental risks. The study will run from August 2025 through October 2026, with primary outcome assessments at 12 months of age.

Turkish Version of the BRIEF-Hammersmith Infant Neurological Examination (HINE)